View from the C-Suite: Shawn Shirazi, Chief Executive Officer, Theralase Technologies Inc., tells his company's story. Filmed on December 18, 2019
Canada NewsWire
TORONTO, Jan. 8, 2020
https://youtu.be/5mHuzRGWvRo
TORONTO, Jan. 8, 2020 /CNW/ - The View from the C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View from the C-Suite videos visit www.tmxmoney.com/en/news/csuite.html)
About Theralase Technologies Inc. (TSXV: TLT)
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.
Additional information is available at www.theralase.com and www.sedar.com
About TMX Group (TSX: X)
TMX Group's key subsidiaries operate cash and derivative markets and clearinghouses for multiple asset classes including equities and fixed income. Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, Trayport and other TMX Group companies provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London, Beijing and Singapore. For more information about TMX Group, visit our website at www.tmx.com. Follow TMX Group on Twitter: @TMXGroup.
SOURCE TMX Group Limited
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2020/08/c7289.html
Copyright CNW Group 2020